The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease

Last updated: May 29, 2023
Sponsor: Pusan National University Hospital
Overall Status: Completed

Phase

3

Condition

Esophageal Disorders

Gastroesophageal Reflux Disease (Gerd)

Heartburn (Pediatric)

Treatment

Placebo

Tegoprazan

Clinical Study ID

NCT05871398
H-1909-005-096
  • Ages > 19
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. The investigators aimed to evaluate whether tegoprazan would be more effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux disease (LPRD). Methods: This double-blind, randomized, placebo-controlled trial randomly assigned 35 patients suffering LPRD symptom to two groups: Tegoprazan50mg once daily and placebo. The primary end point was complete resolution rate of LPRD symptoms after 8-week medication, and the secondary endpoints were complete resolution rate of LPRD symptoms after 4-week medication, change of reflux symptom index (RSI) and reflux finding score (RFS) from baseline at 4- and 8-week medication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least one symptom of LPRD (hoarseness, globus, persistent throat discomfort, andfrequent throat clearing) for at least 4 weeks
  • Reflux symptom index > 13 and reflux finding score ≥ 7

Exclusion

Exclusion Criteria:

  • Viral or bacterial laryngopharyngitis at present
  • History of malignancy of head and neck region, esophagus and stomach
  • Previous radiotherapy or endotracheal intubation within three months
  • Previous anti-reflux surgery or gastroesophageal surgery
  • Diagnosis of depression, anxiety, panic, somatoform or other psychotic disorder
  • Taking anti-psychotics, anti-depressants or anti-anxiety drugs
  • Anti-reflux medication such as proton-pump inhibitors (within 4 weeks beforescreening), histamine receptor 2 blockers, antacids or prokinetics (within 2 weeksbefore screening)
  • Need for continuous therapy with non-steroidal anti-inflammatory drugs
  • Pregnant or breastfeeding women, as well as female patients who were not willing touse contraception for the duration of the clinical trial period
  • Abnormal laboratory test values at screening (blood urea nitrogen and serum creatinelevel >1.5 upper limit of normal [ULN]; total bilirubin levels and serum levels ofalanine aminotransferase, aspartate aminotransferase, alkaline phosphatase andgamma-glutamyl transferase > 2 ULN) or
  • Any other conditions or disease that an investigator considered not appropriate forthis study

Study Design

Total Participants: 36
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
October 01, 2019
Estimated Completion Date:
February 28, 2023

Connect with a study center

  • Pusan National University Hospital

    Pusan, 49241
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.